Table 3.
Adverse events of the PAT with TKIs and anti-PD-1 antibodies and their CTCAE grade.
| Adverse events | PAT with TKIs and anti-PD-1 antibodies (n= 47) | |||
|---|---|---|---|---|
| All (%) | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | |
| Clinical symptoms | ||||
| Pruritus | 44.7 (21/47) | 31.9 (15/47) | 10.6 (5/47) | 2.1 (1/47) |
| Hypertension | 42.6 (20/47) | 31.9 (15/47) | 8.5 (4/47) | 2.1 (1/47) |
| Dermatitis | 34.0 (16/47) | 19.1 (9/47) | 8.5 (4/47) | 6.4 (3/47) |
| Fatigue | 25.5 (12/47) | 19.1 (9/47) | 6.4 (3/47) | 0 |
| Anorexia | 21.3 (10/47) | 12.8 (6/47) | 8.5 (4/47) | 0 |
| Diarrhea | 19.1 (9/47) | 8.5 (4/47) | 4.2 (2/47) | 6.4 (3/47) |
| HRSR | 19.1 (9/47) | 6.4 (3/47) | 10.6 (5/47) | 2.1 (1/47) |
| Stomatitis | 10.6 (5/47) | 6.4 (3/47) | 4.2 (2/47) | 0 |
| Dysphonia | 6.4 (3/47) | 4.2 (2/47) | 2.1 (1/47) | 0 |
| Pneumonitis | 6.4 (3/47) | 6.4 (3/47) | 0 | 0 |
| Laboratory test | ||||
| Proteinuria | 31.9 (15/47) | 21.3 (10/47) | 8.5 (4/47) | 2.1 (1/47) |
| Neutropenia | 27.7 (13/47) | 25.6 (12/47) | 2.1 (1/47) | 0 |
| Thrombocytopenia | 25.6 (12/47) | 21.3 (10/47) | 2.1 (1/47) | 2.1 (1/47) |
| Anemia | 25.6 (12/47) | 23.4 (11/47) | 2.1 (1/47) | 0 |
| Hypothyroidism | 21.3 (10/47) | 19.1 (9/47) | 2.1 (1/47) | 0 |
PAT, postoperative adjuvant therapy; TKIs, tyrosine kinase inhibitors; anti-PD-1, anti-programmed cell death protein 1; CTCAE, common terminology criteria for adverse events; HRSR, hand-foot skin reaction.